The global exosomes market size was estimated at USD 3.00 million in 2016. However, exponential growth in revenue is anticipated over the coming decade due to granular and bottom-up efforts made by researchers in the field. Rising number of research grants and projects by various research organizations will also contribute toward market growth.
Projects are being undertaken to develop methods that enable efficient isolation and characterization of exosomal vesicles. The participation of exosomes in different functions and availability of a wide variety of pathways are expected to fuel research in the field, thereby leading to revenue generation. Rise in research funding is also expected to boost the market in the coming years. For instance, in August 2013, the U.S. National Institutes of Health announced the funding of USD 17 million for 24 research projects focusing on extracellular RNA.
Small companies flooding the marketplace and the development of novel platforms and advanced technologies will also drive market growth over the forecast period. New platforms enable detection of low abundant membrane proteins and this detection can be carried out even in the background of complex plasma proteins.
In addition to this, the role of exosomes in providing insights for the diagnosis of pathological conditions is anticipated to increase its adoption in the research arena. Exosomes belong to the family of nanovesicles, which serve many functions in the diagnosis and therapy of multiple diseases.
On the basis of workflow, isolation methods and downstream analysis are two major segments. The downstream analysis accounted for the larger share owing to the growing need for advanced technologies and instrumentation for downstream processing.
Isolation methods comprise ultracentrifugation, immunocapture, precipitation, and filtration. While ultracentrifugation dominated the segment with respect to revenue, other methods are anticipated to witness a similar growth pattern due to fragmented research being carried out in isolation protocols. Ultracentrifugation is considered to be the gold standard of purification. Easy availability of instruments and reagents for this method is attributive to its large market share.
Within the downstream analysis segment, flow cytometry dominated the market with respect to revenue owing to higher usage in the process. Availability of clever solutions and straightforward protocols for the cytometric method has supported the growth of this sub-segment. RNA analysis using NGS and PCR is expected to witness lucrative growth in the coming years due to a rise in the number of platforms installed for NGS analysis.
Different types of biomolecules are used for exosomal analysis; these include non-coding RNAs, mRNA (exoRNA), peptides or proteins, DNA fragments, and lipids. Non-coding RNAs constitute miRNAs and long non-coding RNAs (lncRNAs).
Non-coding RNAs are being increasingly used for research purposes and this has enabled them to emerge as the dominant segment. Functions of lncRNA are believed to be associated with mental and psychiatric disorders, tumor growth, and imprinting. Development of specific protocols for research in non-coding RNA and the prediction of its secondary structure is anticipated to drive the growth of this segment.
Application of pre-clinical animal models in research to assess the feasibility of detecting tumor-associated genetic mutations in circulating exoDNA is expected to boost the DNA fragments segment in the coming years. Exosomal DNA possesses translational potential as a circulating biomarker for cancer, a factor that also supports the growth of this segment.
By way of application, cancer dominates the overall exosomes market due to the growing role of exosomes in cancer research. Contribution of exosomes for tumorigenesis, chemotherapeutic resistance, and development of novel cancer treatments through the identification of cancer biomarkers is also responsible for the growth of this segment. Exosomes are used not only as a drug delivery method and for chemotherapeutic sensitization but also as a non-invasive biomarker. This has led to increased R&D on these messengers.
The neurodegenerative disorders segment offers significant scope for expansion, owing to the study of exosomes and related extracellular vesicles being carried out in the field. Research in this segment is vital in unveiling the use of exosomes as therapeutic tools for brain disorders as well as biomarkers of the disease state.
North America accounted for the largest revenue share with respect in 2016 and this can be attributed to extensive funding in the U.S. For instance, in March 2017, researchers at the Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine received two grants from the Sohn Conference Foundation for R&D in isolation and characterization of tumor-derived exosomes to study cancer occurrence in children.
Asia Pacific is expected to emerge as the fastest-growing region due to immense potential identified in emerging economies such as China and India. Competitive strategies adopted by players to carry out R&D activities in this sector are thanks to constant government support and this is likely to support the growth of the Asia Pacific market.
Some of the key players in the market are Fujifilm; Thermo Fisher Scientific, Inc.; Danaher; Lonza; Illumina, Inc.; Qiagen; Takara Bio Company; Malvern Instruments Ltd.; Miltenyi Biotec; and MBL International Corporation. Exosome companies are multiplying in number, with new entrants venturing into the industry at a rapid pace.
Companies are engaged in setting up production facilities in order to develop specific exosomes cell lines and capture a greater market share. Intense competition has also been noted with respect to patent filing and the launch of novel products.
Attribute |
Details |
Base year for estimation |
2016 |
Actual estimates/Historical data |
2014 - 2016 |
Forecast period |
2017 - 2030 |
Market representation |
Revenue in USD Million & CAGR from 2017 to 2025 |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Country scope |
U.S., Canada, U.K., Germany, Japan, China, Brazil, South Africa. |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2014 to 2030. For the purpose of this report, Grand View Research has segmented the global exosomes market report on the basis of workflow, biomolecule type, application, and region:
Workflow Outlook (Revenue, USD Million, 2014 - 2030)
Isolation Methods
Ultracentrifugation
Immunocapture on beads
Precipitation
Filtration
Downstream Analysis
Cell Surface Marker Analysis using Flow Cytometry
Protein analysis using Blotting & ELISA
RNA analysis with NGS & PCR
Proteomic analysis using Mass Spectrometry
Others
Biomolecule Type Outlook (Revenue, USD Million, 2014 - 2030)
Non-coding RNAs
mRNA
Proteins /peptides
DNA fragments
Lipids
Application Outlook (Revenue, USD Million, 2014 - 2030)
Cancer
Neurodegenerative diseases
Cardiovascular diseases
Infectious diseases
Others
Regional Outlook (Revenue, USD Million, 2014 - 2030)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
China
Latin America
Brazil
The Middle East and Africa (MEA)
South Africa
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.